227 related articles for article (PubMed ID: 17456829)
1. Evaluation of genetic factors for warfarin dose prediction.
Caldwell MD; Berg RL; Zhang KQ; Glurich I; Schmelzer JR; Yale SH; Vidaillet HJ; Burmester JK
Clin Med Res; 2007 Mar; 5(1):8-16. PubMed ID: 17456829
[TBL] [Abstract][Full Text] [Related]
2. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
3. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
4. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
5. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.
Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
Thromb Haemost; 2006 May; 95(5):782-7. PubMed ID: 16676068
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
7. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
8. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
Ohno M; Yamamoto A; Ono A; Miura G; Funamoto M; Takemoto Y; Otsu K; Kouno Y; Tanabe T; Masunaga Y; Nonen S; Fujio Y; Azuma J
Eur J Clin Pharmacol; 2009 Nov; 65(11):1097-103. PubMed ID: 19582440
[TBL] [Abstract][Full Text] [Related]
9. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
10. [Possible application of pharmacogenomics to warfarin therapy].
Murata M
Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
[TBL] [Abstract][Full Text] [Related]
11. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
[TBL] [Abstract][Full Text] [Related]
13. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
14. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of target genes across the warfarin pharmacological pathway.
Lal S; Jada SR; Xiang X; Lim WT; Lee EJ; Chowbay B
Clin Pharmacokinet; 2006; 45(12):1189-200. PubMed ID: 17112295
[TBL] [Abstract][Full Text] [Related]
16. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
[TBL] [Abstract][Full Text] [Related]
17. [Application of warfarin pharmacogenetics].
Tomek A; Mat'oska V; Kumstýrfová T; Táborský L
Vnitr Lek; 2009 Jun; 55(6):565-9. PubMed ID: 19662888
[TBL] [Abstract][Full Text] [Related]
18. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
[TBL] [Abstract][Full Text] [Related]
19. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
[TBL] [Abstract][Full Text] [Related]
20. Genetic influences on the response to warfarin.
Kamali F
Curr Opin Hematol; 2006 Sep; 13(5):357-61. PubMed ID: 16888441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
